Via the Russian Direct Investment Fund, the authorities established a mechanism for using foreign sites, where the substance for the production of vaccines is sent to, the minister said.
In the evening of June 21, 2021, leading Russian and international cancer experts presented the results of a three-year efficacy study of the Russian...
Brukinsa® (zanubrutinib) is under regulatory review for relapsed, refractory MCL in the Russian Federation with potential approval at the end of the 2021.